EU Steps Up Manufacturing Inspection Efforts

June 1, 2014
Guest Blogger

Pharmaceutical Executive

One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”.

One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”. The European Directorate for the Quality of Medicines & Healthcare, which is responsible for the European Pharmacopoeia but also runs its own inspection operations, has been tightening and updating guidelines on the testing of products.

Pharm Tech‘s Sean Milmo explains how in this article.

Related Content:

News